Inclusion Criteria:

          -  Patients have provided a signed Informed Consent Form

          -  Age: 18-75 years old

          -  Histologically confirmed diagnosis of esophageal squamous cell carcinoma

          -  Patients have Received and progressed on 1 line of prior Fluoropyrimidine, platinum or
             taxane based palliative chemotherapy

          -  Measurable disease in at least 1 diameter by CT scan or MRI as per RECIST 1.1 criteria

          -  Life expectancy ≥ 3 months

          -  Karnofsky score ≥70

          -  Patient has adequate bone marrow and organ function

               -  Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L

               -  Platelets ≥ 75 x 109/L

               -  Hemoglobin ≥ 9.0 g/dL

          -  Patient has adequate liver function

               -  AST and ALT not more than 2.5 times ULN (not more than 5.0 times ULN if there is
                  liver metastasis)

               -  Serum bilirubin ≤ 2 x ULN

          -  Creatinine ≤ 1.5 times ULN

          -  No malabsorption or other gastrointestinal disorders affecting drug absorption.

          -  No serious complications such as active gastrointestinal hemorrhage, perforation,
             jaundice, gastrointestinal obstruction, non cancerous fever > 38 ℃.

          -  Expect good compliance

        Exclusion Criteria:

          -  Patient has received previous treatment with EGFR inhibitors

          -  Patient is currently receiving Phenytoin, rifampin, barbiturates, C Masi Bing

          -  Known severe hypersensitivity to Icotinib or any of the excipients of this product

          -  CNS metastases without radiotherapy and/or surgery

          -  Patients with treated CNS metastases may participate in this trial,except for those
             who must receive hormone therapy and those whose prior hormone therapy for CNS
             metastases is less than 4 weeks

          -  Evidence of clinically active Interstitial Lung Diseases

          -  Severe systemic disease out of control such as unstable or uncompensated
             respiratory,cardiac,liver,renal diseases

          -  Patient has a concurrent malignancy or has a malignancy within 5 years of study
             enrollment, (with the exception of nonmelanoma skin cancer or cervical carcinoma in
             situ

          -  psychiatric illness that would prevent the patient from giving informed consent

          -  Patient is concurrently using other approved or investigational antineoplastic agent

          -  Pregnant or lactating women